Pharmacokinetics of Daptomycin in Critically Ill Pediatric Patients

Area of Science:

• Pharmacology
• Pediatric Critical Care
• Infectious Diseases

Background:

• Daptomycin is a lipopeptide antibiotic used for serious Gram-positive bacterial infections.
• Optimizing daptomycin dosing in critically ill pediatric populations is crucial for effective treatment.
• Limited pharmacokinetic data exists for daptomycin in critically ill children.

Purpose of the Study:

• To evaluate the pharmacokinetics of daptomycin in critically ill pediatric patients.
• To determine optimal dosing strategies for daptomycin in pediatric sepsis and burn patients.
• To assess the need for therapeutic drug monitoring in this population.

Main Methods:

• Pharmacokinetic study involving 4 critically ill pediatric patients (aged 8-14 years).
• Daptomycin administered at 10 mg/kg once daily.
• Plasma concentrations measured to determine area under the concentration-time curve (AUC0-∞) and clearance.

Main Results:

• Area under the concentration-time curve (AUC0-∞) varied widely (123.8–663.9 μg·h/ml).
• Lower daptomycin exposure was observed in septic and burn patients.
• Clearance ranged from 15.1 to 80.7 ml/h/kg, indicating significant interpatient variability.

Conclusions:

• Higher daptomycin doses may be necessary in septic pediatric patients to achieve adequate drug exposure.
• Significant interpatient pharmacokinetic variability suggests a potential role for therapeutic drug monitoring.
• Further research is warranted to establish precise dosing guidelines for daptomycin in critically ill children.